CJ Godfrey, Ph.D.

Group Leader, Sr Principal Scientist I

CJ has 18 years of drug development experience in both pharma and consulting roles and has been applying pharmacometric methods to PK/PD/outcome analysis and decision support for 22 years. His clinical experience spans a broad range of biomarker, safety, and efficacy endpoints with particular emphasis on oncology, rare diseases, inflammation, and viral diseases. He has extensive experience in performing model-based meta-analyses and near-real-time population PK/PD modeling to support informed and timely decision making.

Recent publications by this scientist

Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK‐611) in Children With Metachromatic Leukodystrophy

June 1, 2020

Troy, S., Wasilewski, M., Beusmans, J. and Godfrey, C. (2020), Clin. Pharmacol. Ther., 107: 1394-1404. doi:10.1002/cpt.1752

Pharmacokinetic & pharmacodynamic modeling and simulation of recombinant human arylsulfatase A in patients with metachromatic leukodystrophy: a preliminary evaluation

February 5, 2018

Troy S, Wasilewski M, Godfrey CJ. Poster presented at the 14th Annual WORLDSymposium. San Diego, CA. 5-9 February 2018.

Download PDF

Modeling & simulation: Filling the knowledge gap in rare diseases. Return on Investment on the Utilization of Systems Pharmacology and pharmacometrics in drug development for rare diseases: challenges and opportunities

September 1, 2015

Gastonguay MR and Godfrey CJ. American College of Clinical Pharmacology (ACCP) Workshop, September 26, 2015.